Skip to content
Clinical Trials – home
Not yet recruiting

A study of subcutaneous infliximab (CT-P13) versus intravenous infliximab for induction therapy in patients with active Crohn’s disease or ulcerative colitis

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

People with active Crohn’s disease or ulcerative colitis have inflammation in the intestines that causes pain, diarrhea, and fatigue. The trial tests a medicine called infliximab, identified by the code name CT-P13, which can be given either as an injection under the skin (subcutaneous) or as a drip into a vein (intravenous). Both forms contain the same active ingredient and are meant to reduce the inflammation that drives the disease.

The purpose of the study is to show that the injection form works at least as well as the drip form in terms of pharmacokinetics, which means how the drug moves through the body, after six weeks of induction therapy. Participants receive the assigned form of the medicine at the start and then return for regular check‑ups over about six months. During these visits, doctors will look at blood samples to measure drug levels, ask about symptoms to see if there is a clinical response (meaning the symptoms improve) or clinical remission (meaning the symptoms are essentially gone), and test simple lab results called biomarker markers that show inflammation is decreasing. Safety will also be monitored by recording any side effects or reactions at the injection site.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Visit (Week 0)

    You will attend the clinic on the first day of the study, called Week 0. During this visit, the study team will record your medical history, perform physical measurements, and collect blood samples for baseline laboratory tests.

    If you are assigned to the intravenous (IV) arm, you will receive infliximab as a powder that is mixed into a solution and infused through a vein. The dose is 5 mg per kilogram of your body weight, given as a single infusion on this day.

    If you are assigned to the subcutaneous (SC) arm, you will receive infliximab as a pre‑filled syringe or pen containing 480 mg of medication. The injection is placed under the skin once on this day.

  2. Step 2

    Second Dose Visit (Week 2)

    Two weeks after the baseline visit, you will return for the second dose. The same administration route and dose that you received at Week 0 will be repeated.

    Additional blood samples will be taken to check for the presence of antibodies against infliximab and to monitor safety, including any injection‑site or allergic reactions.

  3. Step 3

    Third Dose and Primary Assessment (Week 6)

    Six weeks after the first dose, you will receive the third dose of infliximab using the same method as before (IV infusion or SC injection).

    On this visit, the study will measure the drug concentration in your blood at the lowest point before the next dose (called the trough level) to evaluate how the medication is processed in your body.

    The clinical team will also assess your disease activity, asking you to report symptoms and completing questionnaires that measure pain, stool frequency, and overall well‑being.

    Blood and stool samples will be collected to evaluate biomarkers such as fecal calprotectin and C‑reactive protein (CRP), which help determine how the disease is responding to treatment.

  4. Step 4

    Final Follow‑Up Visit (Week 24)

    Approximately six months after the first dose, you will attend the final study visit. No additional dose of infliximab is scheduled for this visit.

    The study will repeat the blood trough level measurement, biomarker tests, and clinical assessments performed at Week 6 to evaluate the durability of the treatment effect.

    You will complete the same quality‑of‑life and treatment‑satisfaction questionnaires that were used earlier, allowing comparison of your condition over time.

Who can join the trial?

9 criteria

  • Be a man or woman between 18 and 75 years old.
  • Have inflammatory bowel disease (either Crohn's disease or ulcerative colitis) diagnosed at least 3 months ago using the ECCO criteria, and the disease must be moderately to severely active (for Crohn's disease a Harvey‑Bradshaw Index score of 8‑16; for ulcerative colitis a partial Mayo score of 5‑9).
  • Have already tried standard medicines (such as corticosteroids alone or together with thiopurines and 5‑aminosalicylates for ulcerative colitis, or corticosteroids and/or immunomodulators for Crohn's disease) without enough improvement.
  • Show at least one clear sign of active disease on a lab test, a scope exam (endoscopy), or imaging scan (cross‑sectional imaging). For Crohn's disease this can be ulcers seen on endoscopy, inflammation on scans, or a high level of fecal calprotectin (a stool test). For ulcerative colitis it can be an endoscopic Mayo subscore of 2 or higher.
  • Plan to start treatment with infliximab CT‑P13 (a medication given by injection) as part of normal medical care.
  • Have received full information about the study, agree to take part, and consent to the use of personal data.
  • Be covered by a social security plan or similar health benefit.
  • If you are a woman of child‑bearing age, you must use reliable contraception (such as hormonal methods, an intrauterine device, tubal occlusion, or complete abstinence) starting at least 30 days before the first dose and continue for at least 6 months after the last dose.
  • Women who are not of child‑bearing age (for example, those who are postmenopausal, have had a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, are over 55 with no periods for 12 months, or have low hormone levels confirmed by a high follicle‑stimulating hormone (FSH) level) do not need contraception.

Who cannot join the trial?

14 criteria

  • Receiving a combination of medicines that change the immune system, known as an immunomodulator.
  • Being judged by the doctor to have a high chance of needing surgery within the next three months.
  • Having taken the medicines thiopurine or methotrexate within the four weeks before the first study visit (these drugs affect the immune system).
  • Having Crohn’s disease with mainly problems around the anus and perineum, where a fistula (an abnormal connection) is the main reason for using infliximab.
  • Being allergic (having hypersensitivity) to the active ingredient infliximab, to mouse‑derived proteins (murine proteins), or to any other substances listed in the drug’s information sheet (SmPC).
  • Having active tuberculosis (a serious lung infection) or other severe infections such as sepsis (body‑wide infection), abscesses (pockets of pus), or infections that take advantage of a weak immune system (opportunistic infections).
  • Having taken oral antibiotics within the past two weeks, or an injection of antibiotics within the past four weeks, or any serious infection in the last six months, or repeated shingles (herpes zoster) or other chronic infections in the past six weeks.
  • Not having had a test to check for antibodies against anti‑TNF drugs before the study (these tests help predict reactions to the medication).
  • Having moderate or severe heart failure, classified as NYHA class III or IV (meaning the heart cannot pump blood well and causes serious symptoms).
  • Being pregnant or breastfeeding.
  • Being an adult who is under legal protection, such as a public guardian.
  • Having used infliximab before.
  • Having an acute severe flare of ulcerative colitis (a sudden, serious worsening of the disease).
  • Being expected to be hospitalized very soon, as judged by the investigator.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Remsima

    This is a biosimilar version of infliximab that is given by intravenous infusion. In the trial it is used as the comparator, meaning it represents the standard way the drug is usually given through a vein. Researchers look at how the medicine behaves in the body and how well it works when given this way.

  • Remsima

    This formulation of infliximab is provided in a pre‑filled syringe for subcutaneous injection. Participants inject the medicine just under the skin. In the study it is one of the test treatments, and the goal is to see if this easier, needle‑under‑the‑skin method works as well as the intravenous infusion.

  • Remsima

    This version of infliximab comes in a pre‑filled pen that also delivers the drug subcutaneously. Like the syringe, it allows the patient to inject the medicine under the skin. It is another test treatment in the trial, used to compare the safety, effectiveness, and how the drug is absorbed with the traditional intravenous infusion.

What is already known about the treatment

  • Remsima 100 mg powder for concentrate for solution for infusion

    This medication is mixed with a liquid and given by intravenous infusion, meaning it goes directly into a vein. It is an approved biosimilar of infliximab and is widely used in clinical practice and research. It is mainly used to treat active Crohn’s disease and ulcerative colitis, two types of inflammatory bowel disease. The drug works by attaching to a protein called TNF‑alpha, which reduces inflammation, and it belongs to the class of monoclonal antibody anti‑TNF agents.

  • Remsima 120 mg solution for injection in pre‑filled syringe

    This version is a ready‑to‑use liquid that is injected under the skin (subcutaneous injection). It is an approved biosimilar of infliximab and is recognized in medical literature as an alternative to the intravenous form. It is used to treat active Crohn’s disease and ulcerative colitis. It blocks the inflammatory protein TNF‑alpha, acting as a monoclonal antibody anti‑TNF drug.

  • Remsima 120 mg solution for injection in pre‑filled pen

    This product is a liquid that is self‑administered under the skin using a pre‑filled pen device. It is also an approved infliximab biosimilar and is documented in current medical sources. It is prescribed for patients with active Crohn’s disease or ulcerative colitis. Like the other forms, it binds to TNF‑alpha to lower inflammation and is classified as a monoclonal antibody anti‑TNF therapy.

Investigated diseases

  • Crohn's disease

    chronic inflammation that can affect any part of the digestive tract, most often the end of the small intestine and the beginning of the colon. It usually starts with mild abdominal pain and diarrhea, and over time the inflammation can cause thickening of the intestinal wall, leading to narrowing, fistulas, or abscesses. Symptoms may come and go, with periods of worsening followed by calmer phases.

  • Ulcerative colitis

    long‑lasting inflammation limited to the lining of the large intestine and rectum. It often begins with frequent loose stools that may contain blood, and the inflammation can spread upward along the colon. As the disease continues, the colon wall becomes irritated and may develop ulcers, causing increased urgency and discomfort. Flare‑ups can alternate with times of fewer symptoms.

Trial detailsLast updated 22 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2026-526227-22-00Protocol codePASSPORT-2Estimated enrolment80 patientsSponsorCentre Medico Chirurgical Ambroise Pare Hartmann

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.